These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16388406)

  • 21. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
    Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins.
    Filppula AM; Hirvensalo P; Parviainen H; Ivaska VE; Lönnberg KI; Deng F; Viinamäki J; Kurkela M; Neuvonen M; Niemi M
    Drug Metab Dispos; 2021 Aug; 49(8):658-667. PubMed ID: 34045219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
    Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
    Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes.
    Niwa T; Shiraga T; Takagi A
    Biol Pharm Bull; 2005 Sep; 28(9):1805-8. PubMed ID: 16141567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
    J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
    Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
    Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells.
    Yamasaki D; Nakamura T; Okamura N; Kokudai M; Inui N; Takeuchi K; Watanabe H; Hirai M; Okumura K; Sakaeda T
    Eur J Pharm Sci; 2009 May; 37(2):126-32. PubMed ID: 19429419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.
    Wen X; Wang JS; Backman JT; Laitila J; Neuvonen PJ
    Drug Metab Dispos; 2002 Jun; 30(6):631-5. PubMed ID: 12019187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
    Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
    Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex difference in inhibition of in vitro mexazolam metabolism by various 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in rat liver microsomes.
    Ishigami M; Takasaki W; Ikeda T; Komai T; Ito K; Sugiyama Y
    Drug Metab Dispos; 2002 Aug; 30(8):904-10. PubMed ID: 12124308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
    Wen X; Wang JS; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone.
    Korhonen T; Turpeinen M; Tolonen A; Laine K; Pelkonen O
    J Steroid Biochem Mol Biol; 2008 May; 110(1-2):56-66. PubMed ID: 18356043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.
    Katoh M; Nakajima M; Yamazaki H; Yokoi T
    Pharm Res; 2000 Oct; 17(10):1189-97. PubMed ID: 11145223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
    Polli JW; Hussey E; Bush M; Generaux G; Smith G; Collins D; McMullen S; Turner N; Nunez DJ
    Xenobiotica; 2013 Jun; 43(6):498-508. PubMed ID: 23256625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
    Ufer M; Svensson JO; Krausz KW; Gelboin HV; Rane A; Tybring G
    Eur J Clin Pharmacol; 2004 May; 60(3):173-82. PubMed ID: 15054565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
    Pasha MK; Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
    Biomed Chromatogr; 2006 Mar; 20(3):282-93. PubMed ID: 16143964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
    Eagling VA; Tjia JF; Back DJ
    Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.
    Kajinami K; Takekoshi N; Saito Y
    Cardiovasc Drug Rev; 2003; 21(3):199-215. PubMed ID: 12931254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
    Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.